Home / Resource Library / BRENTUXIMAB VEDOTIN CONSOLIDATION THERAPY AFTER AUTOLOGOUS STEM-CELL TRANSPLANTATION IN PATIENTS WITH HIGH-RISK HODGKIN’S LYMPHOMA: MULTI-CENTER REAL-LIFE EXPERIENCEBRENTUXIMAB VEDOTIN CONSOLIDATION THERAPY AFTER AUTOLOGOUS STEM-CELL TRANSPLANTATION IN PATIENTS WITH HIGH-RISK HODGKIN’S LYMPHOMA: MULTI-CENTER REAL-LIFE EXPERIENCE EHA 2020